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ABSTRACT 
Co-Crystals are crystalline materials formed by bonding between a drug and co-former. This alternative approach help to overcome many 
issues arise during preformulation like solubility, dissolution characteristics, compressibility, and product stability. The co-crystal engineering 
is done by following hydrogen bonding rules and molecular structure by using Cambridge structural database. co-crystals can be synthesized by 
solution mediated and solvo thermal methods. The formation of the crystals was analyzed by some analytical techniques like FTIR, DSC etc. The 
regulation of pharmaceutical co-crystals and their formulations shows considerable effect on development and quality control strategies and 
also to the value of intellectual properties. 
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Co-crystals are solids that are crystalline materials 
composed of two or more molecules in the same crystal 
lattice [1] in  a definite stoichiometric ratio where the 
arrangement in the crystal latticeand is  not based on ion 
pairing[2]. 
Pharmaceutical activeingredients (APIs) exists as 
polymorphs, solvates, hydrates, salts, crystals and  
amorphous  solids. Each form displays unique 
physicochemical properties that caninfluence the 
bioavailability, manufacturability purification, stability and 
other performance characteristics of the drugs[3][4] . 
The most thermodynamically stable form is the crystalline 
form of the compound[3][4][5]. An alternative method for 
enhancement of several pharmaceutical issues raised during 
preformulation[2]and formulation development e.g. by 
solubility, dissolution, bioavailability, chemical stability, 
decreasing hygroscopicity modulation is possible by 
cocrystallisation[6][7],while keeping the pharmacological 
effect of drug unchanged[8][9].where the components are 
arranged in the crystal lattice mainly based on ion pairing, 
the components in cocrystalsare assembled via weaker 
interactions, such as e.g., hydrogen bonding, π-π-stacking or 
van der Waals interactions[2]. 
Solubility is one of the important physicochemical 
properties that needs to be evaluatedduring the drug 
discovery and development process, since it is a significant 
factor that affects thedissolution rate and consequently, the 
oral absorption of the drug[10]. 
The substantial use of co-crystallization process in 
pharmaceutical industry has been accelerated by several 
widely publicized cases in the past few decades. For 
example, thalidomide was marketed as a sedative anti-
nausea agent. However, while (R)-(+)-thalidomide served as 
a sedative, its optical isomer (S)-(−)-thalidomide was 
tragically found to act as a teratogen, resulting in the 
malformation of limbs in newborn. An Another example 
from1998, observing oral bioavailability problems due to 
polymorph of ritanovir in .an another example in 2008 
leading to recall of rotigotine(Neupro) in the United States 
and in Europe because of the unexpected appearance of a 
new polymorph during storage. So maintaining the quality 
by increasing the stability parameters has got significance in 
the pharmaceutical industry [11] . 
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USES OF CO-CRYSTALS:  
Improved bioavailabilityof an API[12] 
It is importantthat the bioavailabilityof a drug should 
satisfythe regulations. a verylow bioavailability causesa drug 
ineffective whereas a high dose could betoxic. The 
bioavailability of an API is mainly dependent on its solubility 
and dissolution rates[9], which in  turn, are dependent  on the 
formulation of the API. The solubility of polymorphs are 
nearly 10 times more than amorphous form, whereas crystal 
forms has hundreds of times greater than amorphous 
form[9][13]. 
Increased resistance to hydrate formation[12][14] 
Due to the presence of moisture aconversion of an API intoa 
hydrate form could bring about undesired physiochemical 
properties such as low bioavailability and can also implicate 
the processing, formulation, packaging and storage of the 
API. 
Even after an API has been formulated into a drug product, 
there are some chances for cause of hydration. For example, 
using of some pharmaceutical techniques which employs 
water like granulation, spraydrying, film coating if hydrated 
excipients are used. hydration could be caused if the 
formulation itself has hydrated excipients, hygroscopic 
excipients or stored in moist conditions[14]. 
Improved compactionproperties for tableting 
It has been estimated that only less than 20% of the Active 
Pharmaceutical Ingredients (API) can be processed into 
tablets viadirect compression since most ofthe API’slack 
properties required for direct compression like the flow, 
cohesion, packability, compactibility, compressibility or 
lubricating [15]. 
Recently, attemptswere made to produce alternative solid 
forms ofAPI’sthat are pharmaceutically acceptable, 
thermodynamically stable and better compaction properties. 
This was achieved by co-crystallization. 
Several API’scan’t be done into salt forms due to lack of 
acidic and basic groups on the molecule like paracetamol. a 
biologically safe molecules were produced using co-
crystallization , such as paracetamol- trimethylglycine 
cocrystal[16]. 
DRUG SELECTION: [17] 
The APIshould have at least one functional group selected 
from ether, thioether, alcohol, thiol, aldehyde, ketone, 
thioketone, nitrate ester, phosphate ester, thiophosphate 
ester, ester, thioester, sulfate ester, carboxylic acid, 
phosphinic acid, phosphonic acid, sulfonic acid, amide, 
primary amine, secondary amine, ammonia, tertiary amine, 
imine, thiocyanate, cyanamide, oxime, nitrile diazo, 
organohalide, nitro, S-heterocyclic ring, thiophene, N-
heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, 
peroxide, hydroxamic acid, imidazole, pyridine [18]to form 
bonding with coformers. 
Drugs without tabletting properties and drugs without 
dissolution properties has wide probability of doing co-
crystallization. [19] 
CO FORMER SELECTION. 
Supramolecular synthon approach which utilizes Cambridge 
Structural Database (CSD) which help in selection of bestco-
formers for crystal form screening, Hansen solubility 
parameter and knowledge of hydrogen bonding between co-
former and API[20]are effective tools in co-crystallization. 
co-crystal  former  must  be accepted by regulatory authority 
andhas at least one functional group selected from amine, 
amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, 
carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and 
methyl thio, such that the API and co-crystal former are 
capable of co-crystallizing from a solution phase under 
crystallization conditions[18]. 
Examples [19]:benzoic acid ,succinic acid ,fumaric acid , 
glutaric acid ,glycolic acid ,sorbic acid, oxalic acid ,adipic acid 
,maleic acid ,salicylic acid ,saccharin ,L-tartaric acid 
,nicotinamide ketoglutaric acid, Form A , ketoglutaric acid, 
Form B , malonic acid, Form A ,benzoquinone,2,4-
dihydroxybenozoic acid Form I ,2,4-dihydroxybenozoic acid, 
Form II ,4-hydroxybenzoic acid Isonicotinamide,2,5-
dihydroxybenzoic acid ,2-hydroxybenzoic acid ,trans-
cinnamic acid ,trans-2-hexanoic acid ,L-(+)-lactic acid ,L-(+)-
tartaric acid  ,(+)-camphoric acid ,4-hydroxybenzoic acid, 
Form A ,4-hydroxybenzoic acid, Form C . 
DESIGN OF CO-CRYSTALS[21][3] 
Co-crystallization produces novel pharmaceutical forms 
where the experimental work follows Hydrogen bonding 
rules and knowledge from cambride structural database. 
Co-crystals consist of multiple components in given 
stoichiometric ratio, where different molecular species 
interact by hydrogen bonding and by non-hydrogen 
bonding. 
The use of hydrogen bonding rules and synthons may assist 
in the designing of cocrystal systems and hydrogen bond 
patterns in a number of organic crystals[18]. 
The co-former selection is facilitated by understanding of 
the supramolecular chemistry [22]of the functional groups 
present in a given molecule is essential for designing the co-
crystals. Supramolecular synthons that can occur In common 
functional group in orderto design new co-crystals and 
certain functional groups such as carboxylic acids, amides 
and alcohols are compliant for formation of supramolecular 
heterosynthon[12]. The strong hydrogenbond includes (N-
H---O), (O-H---O), (-N-H---N,) and (O-H---N). The 
weakhydrogen bonds involvesthe −C-H---O and C-H---O=C. 
HYDROGEN BOND DONORS AND ACCEPTORS: 
The number of hydrogen bond donors and acceptors in a co-
former and drug molecules also 
Determinestheextent of success in co-crystallization [23][25]. 
Moleculesthat can form multiple hydrogen bonds are likely 
to form co-crystals with the co-former molecules.  
Etter  and Donohue framed HydrogenBond Rules to predict 
the circumstances under which hydrogen bond interactions 
that result into co-crystals .  
These rulesare as given below:[24] 
a. Mostly all good proton donors (such as –COOH, –NH4+) 
and acceptors (such as –OH, –NH3) 
are utilized in hydrogen bonding. 
b. Six-membered ringintramolecular hydrogen bonds (such 
as C-H. . . O) are formed first in preference to intermolecular 
hydrogen bonds (such as N-H. . . O andO-H. . . O). 
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c. The best proton donors and acceptors available after 
intramolecular hydrogenbond formationthen participate in 
intermolecular hydrogen bonds. 
d. All acidic hydrogen atoms are included in hydrogen 
bonding in the crystal structure.  
CRYSTAL FORMATION AND INFLUENCE OF 
VARIOUS FACTORS ON CRYSTAL HABITAT: 
Habit describes the external shape of a crystal, whereas 
polymorph state refers to the definite arrangement if 
molecules inside the crystal lattice[3]. 
Thermodynamic parameter like solubility, kinetic 
parameters like super saturation, nucleation rate, 
dissolution rate, antisolvent addition rate, and evaporation 
rate phenomenon governs the crystallization[5]. 
CO-CRYSTALS SYNTHESIS: [26][27][28] 
Co-crystals are crystalline materials that contain two or 
moredifferent molecular components in the same crystal 
lattice with well-defined stoichiometric ratios and these 
components are usually APIs and co-formers that are both 
solids at room temperature. Co-crystals have been prepared 
by solution, solid-state, or melt processes largely based on 
trial and error. 
Solution-Mediated Processes: 
The most generally used solution-based method to 
synthesize co-crystals is slow evaporation from solutions 
with equimolaror stoichiometric concentrations of co-crystal 
components[29,30]. 
Solvo-thermal methods:[29,31] heat is used to dissolve  
stoichiometric  amounts of both components, thesolution is 
cooled, andthe co-crystals are then allowed to nucleate and 
grow.  
Gas Anti Solvent (GAS) method: [32][33] 
This approachhave reduced inorganic solvent use during co-
crystal  production. Specifically, carbon dioxide gasaddition 
effectively induces formation and precipitation from 
aqueous solution. 
Itraconazole–succinic acid co-crystal can be effectively 
synthesized by this method.[26] 
Spray-Drying or Freeze-Drying:[34] 
Co-crystals, can also be formed by spray-drying or freeze-
drying API–conformer solutions. These processes feature 
faster solute solidification compared to crystallization in 
aqueous solutions, which may promoteco-crystal production 
by reducing the phase separation and precipitation of low-
solubility components.  
Spray-drying is expected to facilitate the large-scale 
production of pharmaceutical co-crystals by fast, cost – 
effective solvent evaporation.  
Freeze-drying is suitablefor the aseptic production 
ofinjectable solid formulations.  
Thedrawback of this technique is generating less stable 
amorphous solids or metastable crystals 
Co-crystalformation in the presence of a third component by 
a one-step spray drying process has the potential to reduce 
the number of unit operations which are required to 
produce a final pharmaceutical product[34] (e.g. by 
eliminating blending with excipient). Sulfadimidine (SDM), a 
poorly water soluble active pharmaceutical ingredient (API), 
and 4-aminosalicylic acid (4ASA), a hydrophilic molecule, 
were used as model drug and co-former respectively to form 
co-crystals by spray drying in the presence of a third 
component (excipient). 
Example: CBZ–nicotinamide, theophylline co-crystals[35]. 
Freeze-drying is suitable for the aseptic production of 
injectable solid formulations. The drawback of this 
technique is generating less stable amorphous solids or 
metastable crystals[36]. 
Solvent drop grinding and solvent evaporation:[37] 
Solvent drop grinding includes grinding of two materials 
together like solid state grinding with incorporation of small 
quantity of solvent. The solventadded act as catalyst. It is 
anticipated that this approach will open new opportunities 
in both the synthesis and characterization of co-crystals, 
regardless of the inabilities to characterize materials 
synthesized using this method by single-crystal X-ray 
diffraction. 
Slurry Crystallization:[37] 
Slurry crystallization is simple process which includes the 
addition of crystallization solvent in the components i.e. API 
along with its acceptable former. The selection of this 
process is mainly depends upon the physical stability of the 
crystallization solution to co-crystals and its solid former. 
Hot melt extrusion:[38] 
Extrusion is useful method for synthesis of  co-crystals, it 
involves highly efficient mixing and  
Improved surfacecontacts, Co-crystals are prepared  without 
use of solvent. The selection of this method is  primarily 
depends on thermodynamic stability of  compound. This 
method was studied with the use of four models for co-
crystal formation. 
Solvent drop extrusion technique: 
This method is used to optimize and make the process more 
flexible. Solvent drop extrusion technique gives an 
advantage to carry out process at lower temperature. Hot 
melt extrusion method was used in carvedilol and 
nicotinamide cocrystal formation[39]and synthesis of 
carbamazepine:4-aminobenzoic acid co-crystal system [40]. 
Evaporative Co-crystallization:[41] 
Evaporative co-crystallization is a common method of 
generating co-crystals, typically employed for generating 
single crystal co-crystals suitable for diffraction studies to 
elucidate co-crystal structure. The technique involves the 
nucleation and growth of a co-crystal from a solution of both 
co-formers in a solvent, with super saturation provided by 
removal of the solvent from the solution via evaporation. 
Individual co-crystals, or the bulk crystal sample, should be 
harvested before the solution evaporates to dryness to 
ensure recovery of a clean crystal. 
PHYSICOCHEMICAL PROPERTIES 
Particle sizedetermination by microscopic studies:[42] 
The particle size of the carbamazepine pure drug is found 
around 500-800 micrometers and CBZ : oxalic acid co-
crystals were found less when compared to pure drug . the 
length of the needle shaped crystals were around 300-500 
micrometres and the width is very less and nearly around 
120 micrometer.  
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The needle shaped co-crystals has less particle size hence 
solubility might be increased[43]. 
Solubility: the solubility of Carbamazepine pure drug in 
water is 20mg per lit [17.7mg according to drug 
bank][44].The CBZ: Oxalic acid solubility has observed an 
increasein its solubility with 40 mg per litre. 
ANALYTICAL METHODS: 
Fourier transitioninfrared spectrometry:[42] 
IR spectroscopy was conducted using a FTIR  
Spectrophotometer (Bruker opus) and background 
spectrumof carbamazepine and benzoic acidco-crystals was 
collectedatthe wavelength region of 4000–400 cm−1under 
identical conditions.  
Melting point apparatus: 
Melting point is the physical property of solids, which is used 
to determine the purity of the product with sharp melts and 
narrow ranges .High melting point indicates the 
thermodynamically stability of the API’s i.e.the co-former 
with high melting point may increase the thermal stability of 
a drug[14].  
Co-crystals with low melting points can also be beneficial 
when dealing with thermo-labile drugs. The most commonly 
used techniques for determination of melting point and 
thermal analysis are differential scanning calorimetry(DSC) 
and thermal gravimetric analysis (TGA). 
Differential scanning calorimetry:[42] 
Thermal analyses of all CBZ co-crystal screening product 
were tested by a Perkin Elmer. About 10 mg of tested 
samples were put in aluminum pans and covered with a 
pierced lid. Measurements were carried out at a heatingof 10 
◦ C/min in the temperature range of 20 to 300◦ Cwith 
nitrogen flow rate of 20 mL/min. 
Powder X-ray diffraction: 
Thediffraction patterns of pure carbamazepine and co-
crystalare obtained by using Bruker D8 Advance 
Diffractometer. The instrument was equipped with a fine 
focus X-ray tube and each sample was placed on to a 
goniometer head in a silicon sample holder, and data was 
collected while sample was monitored by spinning.[45]. 
REGULATORY ASPECTS OF COCRYSTALS: 
The regulationof pharmaceutical co-crystals and their 
formulations shows considerable affectondevelopment and 
quality control strategies and also to the value of intellectual 
properties[46]. 
The APIs exist in different forms such as solvates, hydrates, 
salts and co-crystals by forming weaker bonds in which  they 
show same therapeutic effect and broken while dissolution 
in stomach[47].An abridged application makes reference to 
the safety and efficacy documentation of an approved 
reference product containing the same active substance. 
Polymorphic forms of a single entity active substance, or of 
salts, co-crystals, hydrates or solvates, will also be 
considered eligible  for  generic  applications  according  to  
Directives 2001/83/EC Article 10(2)(b)  and 2001/82/EC 
13(2)(b) [48]. 
It is crucial concerning the practical application of a co-
crystal of a commercial APIis whether the co-crystal is  in 
some sense a physical mixture and hence might fall within 
current compendial guidelines, or whether the  co-crystal 
should be regarded as a new chemical entity with all the 
concomitant safety and toxicological testing such substances 
require.  
In2012, the FDA (U.S. Food and Drug Administration) has 
issued guidelines to regulate the use of pharmaceutical co-
crystals, and determines that a co-crystal should be 
considered as a drug product intermediate and not as a new 
API[49] . This decision give opportunitiesforuse of co-crystals 
in the pharmaceutical industry and eliminates the need for 
the co-crystal to go through clinical trials necessary if it had 
been considered as a new API, use of co-crystals of APIs for 
new chemical entities and genericproducts. 
Draft version released in August 2016[48], FDA says it has 
provided clear guidelines about the regulatory classification 
of co-crystals and their relationship to solvates and 
hydrates. 
According to FDA: 
1. "From a physical chemistry and regulatory perspective, 
co-crystals can be viewed as a special case of solvates 
and hydrates, wherein the secondcomponent, the co-
former, is not a solvent (including water), and is 
typically nonvolatile,"  
2. co-crystals meeting its requirements are classified 
similar to polymorphs and are not regarded as new 
APIs.  
3. "From a regulatory perspective, drug products that 
aredesigned to contain a new co-crystal are considered 
analogous to a new polymorph of theAPI," 
4. ‘’co-crystals that contain two or more APIs are 
considered to be fixed-dose combination (FDC) 
products rather than new APIs’’. 
5. companies already marketing drugs containing a 
material the agency previously considered to be a co-
crystal can continue to do so, though new applications 
for those products should include evidence of the 
agency's previous co-crystal designation. 
6. For drugs containing or claiming to contain a co-
crystal, FDA says sponsors should submit evidence 
demonstrating that "both the API and the  co-formers 
are present in the unit cell." 
7. Sponsors should show that the API and co-former co-
exist in the co-crystal and interact nonionicallyif both 
components have ionizable functional groups. 
8. Sponsors should demonstrate that the API will be 
substantially dissociated from its co-crystal form 
before the drug reaches the site of pharmacological 
activity. 
9. "Given that the interaction of the API with its co-former 
is of similar magnitude to the interaction of the API 
with solvents in solvates, an in vitro evaluation based 
on dissolution and/or solubility is generally considered 
sufficient to demonstrate that the API dissociates 
fromits co-former before reaching the site of 
pharmacological activity,"  
10. An applicant can have the opportunity to claim for 
consideration of co-crystals with same approval or 
market authorization as given to an API.  
11. The applicability of good manufacturing practices 
(GMP) for active substances or finished pharmaceutical 
products where co-crystals are produced in situ during 
process shall be taken into consideration 
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It concluded that  the regulations of co-crystals 
understanding and other solid forms of API which may 
be of great value to the point of view to get a generic 




Figure 1: showing the formation of cocrystal hydrate/solvate. [50] 
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